Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
Objective. Bone secondary localizations from metastatic castration-resistant prostate cancer are associated with an increase in mortality and a reduction in the patient’s quality of life. Radium-223 is a targeted alpha-therapy approved for the treatment of mCRPC (metastatic castration resistant pro...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-10-01
|
| Series: | Archivio Italiano di Urologia e Andrologia |
| Subjects: | |
| Online Access: | https://www.pagepressjournals.org/index.php/aiua/article/view/8854 |